Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.68 |
| ▸ | HTR2C | P28335 | 3/20 | 0.68 |
| ▸ | HTR2B | P41595 | 3/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28699512 | 1.00 | HTR2A (0.68) | HTR2AHTR2CHTR2BPTGS2PTGS1 | |
| SCHEMBL8132350 | 0.88 | PTGS2 (0.59) | HTR2AHTR2CHTR2BPTGS2PTGS1 | |
| SCHEMBL28691202 | 0.85 | PTGS2 (0.59) | HTR2AHTR2CHTR2BPTGS2PTGS1 | |
| SCHEMBL1475300 | 0.81 | HTR2A (1.00) | HTR2AHTR2CHTR2BALDH1A1MAPK10 | |
| SCHEMBL28705568 | 0.80 | PDE4A (0.49) | HTR2AHTR2CHTR2BPTGS2PTGS1 | |
| SCHEMBL1476138 | 0.80 | HTR2A (0.63) | HTR2AHTR2CHTR2BPTGS2PTGS1 | |
| SCHEMBL22245041 | 0.79 | HTR2A (0.48) | HTR2AHTR2CHTR2BPTGS2PTGS1 | |
| SCHEMBL21863402 | 0.79 | POLB (0.46) | HTR2AHTR2CHTR2BPTGS2PTGS1 | |
| SCHEMBL28699510 | 0.79 | PDE4A (0.50) | HTR2AHTR2CHTR2BPTGS2PTGS1 | |
| SCHEMBL29374174 | 0.79 | PDE4A (0.61) | HTR2AHTR2CHTR2BPTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2020-02-20 | — | — | US | disclosed |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | HTR2A 4463/4885HTR2C 4411/4885HTR2B 3985/4885 |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | HTR2A 1367/4885HTR2C 2317/4885HTR2B 1686/4885 |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | HTR2A 1367/4885HTR2C 2317/4885HTR2B 1686/4885 |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | HTR2A 4423/4885HTR2C 4390/4885HTR2B 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.